In summary, capecitabine could be a therapeutic option for patients with metastatic colon cancer even though its efficacy is similar to that of conventional therapies such as 5-FU/FA. In these cases, the capecitabine s main comparative advantage would be its easy oral administration and a different side effect profile (a little lower incidence of nausea, diarrhea, stomatitis and neutropenia but a higher incidence of hand-foot syndrome and hyperbilirubinemia). However, it is possible that capecitabine shows a lower effectiveness than other 5-FU/FA infusion regimens used; consequently its indication is yet to be carefully considered.